利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.024 秒)

    Use Of Detection Of Aspartate Transaminase And Lactate Dehydrogenase In Early Evaluation Of Clinical Efficacy Of Antitumor Intervention Measure
    1.
    发明申请
    Use Of Detection Of Aspartate Transaminase And Lactate Dehydrogenase In Early Evaluation Of Clinical Efficacy Of Antitumor Intervention Measure 审中-公开
    使用天冬氨酸转氨酶和乳酸脱氢酶在早期评估抗肿瘤干预措施的临床疗效

    公开(公告)号：US20140206025A1

    公开(公告)日：2014-07-24

    申请号：US14240311

    申请日：2011-08-30

    申请人： Shifang Yang ,  Junsheng Cui ,  Peng Wei ,  Xiangjun Zheng ,  Bing Zhu

    发明人： Shifang Yang ,  Junsheng Cui ,  Peng Wei ,  Xiangjun Zheng ,  Bing Zhu

    IPC分类号： G01N33/50

    CPC分类号： G01N33/5091 ,  G01N33/57484 ,  G01N2333/904 ,  G01N2333/91188 ,  G01N2800/52

    摘要： The present invention relates to a method for early evaluation of clinical efficacy of antitumor intervention measure, comprising evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. In preferable embodiments, the tumor-damaging biomarker(s) is selected from a group consisting of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Lactate Dehydrogenase (LDH); said tumor is multiple myeloma; said antitumor intervention measure is the administration of CPT alone or the administration of CPT in combination with thalidomide.

    摘要翻译： 本发明涉及一种用于早期评估抗肿瘤干预措施的临床疗效的方法，包括通过测定患有肿瘤的患者的血液中的肿瘤损伤性生物标志物的含量是否上升来评估抗肿瘤干预措施的功效 与患者接受至少一种抗肿瘤干预措施后的时间窗内治疗前的基线水平相比。 在优选的实施方案中，肿瘤破坏性生物标志物选自丙氨酸氨基转移酶（ALT），天冬氨酸转氨酶（AST），乳酸脱氢酶（LDH）; 所述肿瘤是多发性骨髓瘤; 所述抗肿瘤干预措施是单独使用CPT或与沙利度胺组合使用CPT。

    Fusion Protein Comprising Circularly Permuted Form Of Trail/Apo2L, Coding Gene And Use Thereof
    3.
    发明申请
    Fusion Protein Comprising Circularly Permuted Form Of Trail/Apo2L, Coding Gene And Use Thereof 有权
    融合蛋白包含循环形式的Trail / Apo2L，编码基因及其用途

    公开(公告)号：US20140342994A1

    公开(公告)日：2014-11-20

    申请号：US14344289

    申请日：2011-09-16

    申请人： Shifang Yang ,  Junsheng Cui ,  Bing Zhu ,  Peng Wei

    发明人： Shifang Yang ,  Junsheng Cui ,  Bing Zhu ,  Peng Wei

    IPC分类号： A61K38/17 ,  A61K45/06 ,  C07K14/47

    CPC分类号： A61K38/1761 ,  A61K38/00 ,  A61K45/06 ,  C07K14/47 ,  C07K14/4747 ,  C07K14/52 ,  C07K14/525 ,  C07K14/70575 ,  C07K14/7151 ,  C07K2319/21 ,  C07K2319/33 ,  C12N15/62 ,  C12N15/63

    摘要： Provided is a fusion protein comprising circularly permuted form of TRAIL, and the fusion protein contains circularly permuted form of TRAIL and oligopeptides located at the N-terminus and/or C-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines. The components of the circularly permuted form of TRAIL from N-terminus to C-terminus are: (a) amino acids 135-281 of TRAIL, (b) a linker, and (c) amino acids 121-135 of TRAIL or amino acids 114-135 of TRAIL or amino acids 95-135 of TRAIL or any fragments of amino acids 95-135 of TRAIL containing amino acids 121-135 of TRAIL. Also provided is a method for treating cancer by using the fusion protein.

    摘要翻译： 提供了包含循环形式的TRAIL的融合蛋白，并且融合蛋白包含位于置换形式的N末端和/或C末端的循环形式的TRAIL和寡肽。 寡肽含有由3-10组氨酸组成的重复序列。 从N末端到C末端的循环形式的TRAIL的组分是：（a）TRAIL的氨基酸135-281，（b）接头，和（c）TRAIL或氨基酸的氨基酸121-135 TRAIL的114-135或TRAIL的氨基酸95-135或含有TRAIL的第121-135位氨基酸的TRAIL的任何氨基酸95-135的片段。 还提供了通过使用融合蛋白治疗癌症的方法。

    HPV antigen fusion protein vaccine compositions and uses thereof
    4.
    发明授权
    HPV antigen fusion protein vaccine compositions and uses thereof 有权
    HPV抗原融合蛋白疫苗组合物及其用途

    公开(公告)号：US08187606B2

    公开(公告)日：2012-05-29

    申请号：US12446382

    申请日：2007-10-19

    申请人： Bing Zhu ,  Shifang Yang ,  Junsheng Cui

    发明人： Bing Zhu ,  Shifang Yang ,  Junsheng Cui

    IPC分类号： A61K39/00

    CPC分类号： A61K39/12 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/005 ,  C07K14/4725 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20034

    摘要： The present invention provides a fusion protein comprising an immunostimulatory polypeptide and a mutant E7 protein of a human papilloma virus. The present invention also provides a gene encoding the fusion protein, expression vectors containing the gene, a pharmaceutical composition comprising the fusion protein, a method for treating or preventing a human papilloma virus related disease by using the fusion protein and uses of the fusion protein in the preparation of a medicament for the treatment or prevention of the human papilloma virus related disease.

    摘要翻译： 本发明提供了包含免疫刺激多肽和人乳头瘤病毒的突变E7蛋白的融合蛋白。 本发明还提供了编码融合蛋白的基因，含有该基因的表达载体，包含该融合蛋白的药物组合物，通过使用融合蛋白治疗或预防人乳头状瘤病毒相关疾病的方法以及融合蛋白的用途 制备用于治疗或预防人乳头状瘤病毒相关疾病的药物。

    HPV ANTIGEN FUSION PROTEIN VACCINE COMPOSITIONS AND USES THEREOF
    5.
    发明申请
    HPV ANTIGEN FUSION PROTEIN VACCINE COMPOSITIONS AND USES THEREOF 有权
    HPV抗原蛋白融合蛋白组合物及其用途

    公开(公告)号：US20100158930A1

    公开(公告)日：2010-06-24

    申请号：US12446382

    申请日：2007-10-19

    申请人： Bing Zhu ,  Shifang Yang ,  Junsheng Cui

    发明人： Bing Zhu ,  Shifang Yang ,  Junsheng Cui

    IPC分类号： A61K39/00 ,  C07H21/00 ,  A61P37/04 ,  A61P31/12 ,  A61P31/14

    CPC分类号： A61K39/12 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/005 ,  C07K14/4725 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20034

    摘要： The present invention provides a fusion protein comprising an immunostimulatory polypeptide and a mutant E7 protein of a human papilloma virus. The present invention also provides a gene encoding the fusion protein, expression vectors containing the gene, a pharmaceutical composition comprising the fusion protein, a method for treating or preventing a human papilloma virus related disease by using the fusion protein and uses of the fusion protein in the preparation of a medicament for the treatment or prevention of the human papilloma virus related disease.

    摘要翻译： 本发明提供了包含免疫刺激多肽和人乳头瘤病毒的突变E7蛋白的融合蛋白。 本发明还提供了编码融合蛋白的基因，含有该基因的表达载体，包含该融合蛋白的药物组合物，通过使用融合蛋白治疗或预防人乳头状瘤病毒相关疾病的方法以及融合蛋白的用途 制备用于治疗或预防人乳头状瘤病毒相关疾病的药物。